Skip Navigation LinksHome > January 2011 - Volume 17 - Issue 1 > Real‐time tool to display the predicted disease course and t...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21386
Original Clinical Articles

Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease

Siegel, Corey A. MD, MS1; Siegel, Lori S. PhD, PE2; Hyams, Jeffrey S. MD3; Kugathasan, Subra MD4; Markowitz, James MD5; Rosh, Joel R. MD6; Leleiko, Neal MD, PhD7; Mack, David R. MD8; Crandall, Wallace MD9; Evans, Jonathan MD10; Keljo, David J. MD, PhD11; Otley, Anthony R. MD, MSc12; Oliva‐Hemker, Maria MD13; Farrior, Sharmayne RN, BSN18; Langton, Christine R. MSW, MPH3; Wrobel, Iwona T. MD14; Wahbeh, Ghassan MD15; Quiros, J. Antonio MD16; Silber, Gary MD17; Bahar, Ron J. MD18; Sands, Bruce E. MD, MS19; Dubinsky, Marla C. MD18

Collapse Box

Abstract

Background:: Immunomodulators and biologics are effective treatments for children with Crohn's disease (CD). The challenge of communicating the anticipated disease course with and without therapy to patients and parents is a barrier to the timely use of these agents. The aim of this project was to develop a tool to graphically display the predicted risks of CD and expected benefits of therapy.

Methods:: Using prospectively collected data from 796 pediatric CD patients we developed a model using system dynamics analysis (SDA). The primary model outcome is the probability of developing a CD‐related complication. Input variables include patient and disease characteristics, magnitude of serologic immune responses expressed as the quartile sum score (QSS), and exposure to medical treatments.

Results:: Multivariate Cox proportional analyses show variables contributing a significant increase in the hazard ratio (HR) for a disease complication include female gender, older age at diagnosis, small bowel or perianal disease, and a higher QSS. As QSS increases, the HR for early use of corticosteroids increases, in contrast to a decreasing HR with early use of immunomodulators, early or late biologics, and early combination therapy. The concordance index for the model is 0.81. Using SDA, results of the Cox analyses are transformed into a simple graph displaying a real‐time individualized probability of disease complication and treatment response.

Conclusions:: We have developed a tool to predict and communicate individualized risks of CD complications and how this is modified by treatment. Once validated, it can be used at the bedside to facilitate patient decision making. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.